176 related articles for article (PubMed ID: 21861100)
1. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
Tanaka T; Yamasaki R; Omura H; Hino N
Int J Hematol; 2011 Sep; 94(3):221. PubMed ID: 21861100
[No Abstract] [Full Text] [Related]
2. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; Vande Broek I; De Raeve H; Coulton L; Van Camp B; Croucher P; Vanderkerken K
Cancer Res; 2009 Jul; 69(13):5307-11. PubMed ID: 19531653
[TBL] [Abstract][Full Text] [Related]
4. Myeloma: diagnosis complications and supportive care.
Morgan G
Hematology; 2012 Apr; 17 Suppl 1():S109-11. PubMed ID: 22507795
[TBL] [Abstract][Full Text] [Related]
5. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
Fröhlich K; Holle JU; Aries PM; Gross WL; Moosig F
Ann Rheum Dis; 2011 Jul; 70(7):1344-5. PubMed ID: 21173019
[No Abstract] [Full Text] [Related]
6. Effects of bortezomib on bone disease in multiple myeloma.
Drake MT; Rajkumar SV
Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
[No Abstract] [Full Text] [Related]
7. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
Wang HH; Tsui J; Wang XY; Liu SS; Li J
Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
[No Abstract] [Full Text] [Related]
8. Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
Wondergem MJ; Grünberg K; Wittgen BP; Sonneveld P; Zweegman S
Histopathology; 2009 Apr; 54(5):631-3. PubMed ID: 19302537
[No Abstract] [Full Text] [Related]
9. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
[No Abstract] [Full Text] [Related]
10. Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
Siniscalchi A; Dentamaro T; Perrotti A; Tatangelo P; de Fabritiis P; Caravita T
Ann Hematol; 2010 Aug; 89(8):821-2. PubMed ID: 19953253
[No Abstract] [Full Text] [Related]
11. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
[No Abstract] [Full Text] [Related]
12. Concurrent radiation therapy and bortezomib in myeloma patient.
Berges O; Decaudin D; Servois V; Kirova YM
Radiother Oncol; 2008 Feb; 86(2):290-2. PubMed ID: 18199515
[No Abstract] [Full Text] [Related]
13. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
[No Abstract] [Full Text] [Related]
14. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.
Minarik J; Scudla V; Tichy T; Pika T; Bacovsky J; Lochman P; Zadrazil J
Leuk Lymphoma; 2012 Feb; 53(2):330-1. PubMed ID: 21883030
[No Abstract] [Full Text] [Related]
15. Bortezomib therapy following first relapse.
Orlowski RZ;
Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
[No Abstract] [Full Text] [Related]
16. Proteasome inhibitor for treatment of multiple myeloma.
Ahmad K
Lancet Oncol; 2005 Aug; 6(8):546. PubMed ID: 16094754
[No Abstract] [Full Text] [Related]
17. RAS mutation status and bortezomib therapy for relapsed multiple myeloma.
Smith D; Armenteros E; Percy L; Kumar M; Lach A; Herledan G; Stubbs M; Downward J; Yong K
Br J Haematol; 2015 Jun; 169(6):905-8. PubMed ID: 25580780
[No Abstract] [Full Text] [Related]
18. Individualizing cancer therapy.
Gertz MA; Tadmor T
Leuk Lymphoma; 2010 Sep; 51(9):1585-7. PubMed ID: 20578822
[No Abstract] [Full Text] [Related]
19. Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment.
Szturz P; Adam Z; Vašků V; Feit J; Krejčí M; Pour L; Hájek R; Mayer J
Leuk Lymphoma; 2013 Jun; 54(6):1324-6. PubMed ID: 23061634
[No Abstract] [Full Text] [Related]
20. Experiences with bortezomib in multiple myeloma - from Phase II studies to daily practice.
Schmitt S; Bertsch U; Goldschmidt H
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):494-6. PubMed ID: 20557858
[No Abstract] [Full Text] [Related]
[Next] [New Search]
